ZetaGen Therapeutics

ZetaGen Therapeutics

Signal active

Organization

Contact Information

Overview

ZetaGen Therapeutics is commercializing a small molecule-based osteoinductive platform technology to develop bone growth products that activate a novel molecular pathway.

ZetaGen Therapeutics's goal is to halt cancer, reduce pain, and rebuild bones. The company's solution has the potential to revolutionize the treatment of bone-related injuries, operations, and diseases, resulting in better outcomes for both patients and doctors.

About

Industries

Health Care, Medical Device, Therapeutics

Founded

2015

Employees

11-50

Headquarters locations

New York, United States, North America

Social

N/A

Profile Resume

ZetaGen Therapeutics headquartered in New York, United States, North America, operates in the Health Care, Medical Device, Therapeutics sector. The company focuses on Health Care and has secured $1.0B in funding across 72 round(s). With a team of 11-50 employees, ZetaGen Therapeutics is actively contributing to advancements in Health Care. Their latest funding round, Series B - ZetaGen Therapeutics, raised $9.8M. Discover more about their projects, partnerships, and impact on our platform.

Employees

imagePlace Nikhil Thakur

Nikhil Thakur

Co-Founder & Chief Medical Officer

imagePlace Bryan Margulies

Bryan Margulies

Co-Founder and Chief Scientific Officer

imagePlace Jessica Pletka

Jessica Pletka

Chief Financial Officer

imagePlace Joe Loy

Joe Loy

Chief Executive Officer

Funding Rounds

Funding rounds

6

Investors

2

Lead Investors

0

Total Funding Amount

$14.4M

Details

5

ZetaGen Therapeutics has raised a total of $14.4M in funding over 5 rounds.

Announcement dateTransaction nameNumber of InvestorsMoney raisedLead Investor
2017Seed1.7M
2018Seed
2022Early Stage Venture
2023Early Stage Venture9.8M

Investors

ZetaGen Therapeutics is funded by 7 investors.

Investor NameLead InvestorFunding RoundPartners
New York Ventures-FUNDING ROUND - New York Venturesundefined
New York Ventures-FUNDING ROUND - New York Ventures9.8M
ZetaGen Therapeutics-FUNDING ROUND - ZetaGen Therapeutics9.8M
Consolidated Investment Group-FUNDING ROUND - Consolidated Investment Group9.8M

Recent Activity

There is no recent news or activity for this profile.